Fig. 5.

Fig. 5. Casirivimab demonstrated severely crippled neutralizing activity against the SARS-CoV-2 beta variant virus. The SARS-CoV-2 Wuhan or beta variant virus was mixed with Casirivimab or Imdevimab, either alone (A and B) or in combination (C) and incubated at 37°C for 1 h before washed three times. Cells were further incubated for 6 h. Viral RNA in the cells was extracted and viral genome equivalents were determined by qRT-PCR as described in the Materials and Methods, and normalized to those of the antibody-untreated control. Neutralization percentage was calculated and plotted (A-C). IC50 of the monoclonal antibody is shown in D. One representative data from two independent experiments is shown. **, p < 0.02.

© J. Microbiol. Biotechnol.